Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, Mitsuzuka K, Inokuchi J, Matsumura M, Shiga K, Naito H, Kohjimoto Y, Kawamura N, Inoue M, Kinoshita H, Hashimoto K, Goto K, Haba R, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: inoue m. Int J Clin Oncol. 2023 Feb;28(2):299-305. doi: 10.1007/s10147-022-02277-8. Epub 2022 Dec 6. Int J Clin Oncol. 2023. PMID: 36472710
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group. Miyake M, et al. Among authors: inoue m. BMC Cancer. 2021 Mar 11;21(1):266. doi: 10.1186/s12885-021-07966-7. BMC Cancer. 2021. PMID: 33706705 Free PMC article.
Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.
Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: inoue m. Int J Clin Oncol. 2022 Jan;27(1):194-201. doi: 10.1007/s10147-021-02041-4. Epub 2021 Oct 2. Int J Clin Oncol. 2022. PMID: 34599725
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: inoue m. Jpn J Clin Oncol. 2022 Sep 18;52(9):1056-1061. doi: 10.1093/jjco/hyac092. Jpn J Clin Oncol. 2022. PMID: 35662340
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, Mitsuzuka K, Inokuchi J, Matsumura M, Shiga K, Naito H, Kohjimoto Y, Kawamura N, Inoue M, Akamatsu S, Terada N, Miyazawa Y, Narita S, Haba R, Sugimoto M. Tohi Y, et al. Among authors: inoue m. Jpn J Clin Oncol. 2023 Oct 4;53(10):984-990. doi: 10.1093/jjco/hyad088. Jpn J Clin Oncol. 2023. PMID: 37496400
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
Washino S, Shirotake S, Takeshita H, Inoue M, Miura Y, Hyodo Y, Kagawa M, Izumi K, Oyama M, Kawakami S, Saito K, Matsuoka Y, Taniuchi S, Shintani A, Miyagawa T. Washino S, et al. Among authors: inoue m. Int J Clin Oncol. 2023 Dec;28(12):1651-1658. doi: 10.1007/s10147-023-02406-x. Epub 2023 Sep 2. Int J Clin Oncol. 2023. PMID: 37658926
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. Yoshida S, et al. Among authors: inoue m. BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z. BMC Urol. 2023. PMID: 36879257 Free PMC article. Clinical Trial.
8,457 results